Ustekinumab en la artritis psoriásica y la enfermedad de Crohn
Ustekinumab in Psoriatic Arthritis and Crohn Disease
Leído
5815
Vecesse ha leído el artículo
2395
Total PDF
3420
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 69 | 109 | 178 |
| 2025 5 | 89 | 60 | 149 |
| 2025 4 | 80 | 47 | 127 |
| 2025 3 | 72 | 24 | 96 |
| 2025 2 | 56 | 25 | 81 |
| 2025 1 | 45 | 21 | 66 |
| 2024 12 | 46 | 20 | 66 |
| 2024 11 | 41 | 53 | 94 |
| 2024 10 | 47 | 40 | 87 |
| 2024 9 | 37 | 20 | 57 |
| 2024 8 | 65 | 41 | 106 |
| 2024 7 | 48 | 29 | 77 |
| 2024 6 | 58 | 28 | 86 |
| 2024 5 | 41 | 24 | 65 |
| 2024 4 | 27 | 14 | 41 |
| 2024 3 | 39 | 34 | 73 |
| 2024 2 | 33 | 24 | 57 |
| 2024 1 | 34 | 17 | 51 |
| 2023 12 | 32 | 14 | 46 |
| 2023 11 | 53 | 19 | 72 |
| 2023 10 | 34 | 12 | 46 |
| 2023 9 | 23 | 21 | 44 |
| 2023 8 | 28 | 11 | 39 |
| 2023 7 | 26 | 24 | 50 |
| 2023 6 | 25 | 22 | 47 |
| 2023 5 | 14 | 9 | 23 |
| 2023 4 | 18 | 12 | 30 |
| 2023 3 | 24 | 20 | 44 |
| 2023 2 | 26 | 12 | 38 |
| 2022 1 | 32 | 28 | 60 |
| 2022 12 | 35 | 23 | 58 |
| 2022 11 | 28 | 23 | 51 |
| 2022 10 | 36 | 23 | 59 |
| 2022 9 | 23 | 33 | 56 |
| 2022 8 | 21 | 30 | 51 |
| 2022 7 | 29 | 28 | 57 |
| 2022 6 | 18 | 22 | 40 |
| 2022 5 | 20 | 30 | 50 |
| 2022 4 | 23 | 39 | 62 |
| 2022 3 | 24 | 43 | 67 |
| 2022 2 | 24 | 18 | 42 |
| 2021 1 | 30 | 32 | 62 |
| 2021 12 | 20 | 35 | 55 |
| 2021 11 | 25 | 37 | 62 |
| 2021 10 | 44 | 39 | 83 |
| 2021 9 | 42 | 40 | 82 |
| 2021 8 | 38 | 31 | 69 |
| 2021 7 | 59 | 35 | 94 |
| 2021 6 | 39 | 34 | 73 |
| 2021 5 | 23 | 34 | 57 |
| 2021 4 | 50 | 60 | 110 |
| 2021 3 | 50 | 28 | 78 |
| 2021 2 | 49 | 21 | 70 |
| 2020 1 | 29 | 10 | 39 |
| 2020 12 | 22 | 15 | 37 |
| 2020 11 | 19 | 16 | 35 |
| 2020 10 | 18 | 8 | 26 |
| 2020 9 | 10 | 5 | 15 |
| 2020 8 | 11 | 17 | 28 |
| 2020 7 | 13 | 9 | 22 |
| 2020 6 | 17 | 18 | 35 |
| 2020 5 | 25 | 29 | 54 |
| 2020 4 | 13 | 16 | 29 |
| 2020 3 | 17 | 17 | 34 |
| 2020 2 | 3 | 2 | 5 |
| 2020 1 | 0 | 7 | 7 |
| 2019 12 | 0 | 7 | 7 |
| 2019 11 | 0 | 4 | 4 |
| 2019 10 | 0 | 2 | 2 |
| 2019 9 | 0 | 4 | 4 |
| 2019 8 | 0 | 7 | 7 |
| 2019 7 | 0 | 13 | 13 |
| 2019 6 | 0 | 14 | 14 |
| 2019 5 | 1 | 19 | 20 |
| 2019 4 | 0 | 4 | 4 |
| 2019 3 | 0 | 1 | 1 |
| 2019 2 | 0 | 5 | 5 |
| 2018 11 | 0 | 7 | 7 |
| 2018 10 | 0 | 1 | 1 |
| 2018 7 | 0 | 1 | 1 |
| 2018 6 | 0 | 5 | 5 |
| 2018 5 | 0 | 8 | 8 |
| 2018 4 | 0 | 3 | 3 |
| 2018 3 | 0 | 2 | 2 |
| 2018 2 | 24 | 10 | 34 |
| 2018 1 | 36 | 9 | 45 |
| 2017 12 | 44 | 11 | 55 |
| 2017 11 | 33 | 8 | 41 |
| 2017 10 | 27 | 9 | 36 |
| 2017 9 | 18 | 10 | 28 |
| 2017 8 | 26 | 8 | 34 |
| 2017 7 | 24 | 12 | 36 |
| 2017 6 | 36 | 15 | 51 |
| 2017 5 | 26 | 14 | 40 |
| 2017 4 | 31 | 17 | 48 |
| 2017 3 | 27 | 21 | 48 |
| 2017 2 | 23 | 9 | 32 |
| 2016 1 | 27 | 17 | 44 |
| 2016 12 | 37 | 7 | 44 |
| 2016 11 | 43 | 7 | 50 |
| 2016 10 | 49 | 17 | 66 |
| 2016 9 | 51 | 17 | 68 |
| 2016 8 | 53 | 16 | 69 |
| 2016 7 | 35 | 9 | 44 |
| 2016 6 | 0 | 12 | 12 |
| 2016 5 | 0 | 13 | 13 |
| 2016 4 | 0 | 2 | 2 |
| 2016 3 | 4 | 3 | 7 |
| 2016 2 | 1 | 3 | 4 |
| 2015 1 | 0 | 23 | 23 |
| 2015 12 | 5 | 20 | 25 |
| 2015 11 | 3 | 23 | 26 |
| 2015 10 | 4 | 14 | 18 |
| 2015 9 | 2 | 8 | 10 |
| 2015 8 | 3 | 6 | 9 |
| 2015 7 | 44 | 2 | 46 |
| 2015 6 | 41 | 17 | 58 |
| 2015 5 | 76 | 21 | 97 |
| 2015 4 | 58 | 33 | 91 |
| 2015 3 | 63 | 21 | 84 |
| 2015 2 | 38 | 14 | 52 |
| 2015 1 | 46 | 13 | 59 |
| 2014 12 | 49 | 10 | 59 |
| 2014 11 | 43 | 14 | 57 |
| 2014 10 | 51 | 24 | 75 |
| 2014 9 | 0 | 1 | 1 |
| 2014 2 | 3 | 0 | 3 |
| 2014 1 | 0 | 1 | 1 |
| 2013 11 | 2 | 0 | 2 |
| 2013 10 | 1 | 0 | 1 |
| 2013 9 | 1 | 1 | 2 |
| 2013 5 | 1 | 2 | 3 |
| 2013 4 | 1 | 1 | 2 |
| 2013 2 | 0 | 1 | 1 |
| 2013 1 | 0 | 1 | 1 |
Mostrar todo
